2013
Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans
Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC, Team F. Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans. Clinical Infectious Diseases 2013, 56: 1498-1504. PMID: 23378285, PMCID: PMC3634308, DOI: 10.1093/cid/cit056.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVACS Index scoreFragility fracturesPhysiologic frailtyVACS IndexMale veteransInhibitor useFracture riskRisk factorsVeterans Aging Cohort Study (VACS) IndexIndex scoreFragility fracture risk factorsICD-9-CM codesProtease inhibitor useFracture risk factorsMarkers of inflammationBody mass indexUpper arm fracturesAlcohol-related diagnosesCox regression modelFirst fragility fractureCause mortalityHIV RNAHemoglobin levelsMass index
2011
Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans
Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, Fraenkel L, Mattocks K, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC, . Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans. PLOS ONE 2011, 6: e17217. PMID: 21359191, PMCID: PMC3040233, DOI: 10.1371/journal.pone.0017217.Peer-Reviewed Original ResearchConceptsBody mass indexHIV infectionUninfected menFragility fracturesFracture riskRisk factorsMale veteransVeterans Aging Cohort Study Virtual CohortCurrent protease inhibitor useFragility fracture risk factorsMedian body mass indexHIV-specific factorsAdjusted hazard ratioProtease inhibitor useFracture risk factorsFragility fracture riskIncident hipHazard ratioInhibitor useUnadjusted riskHIV statusMass indexAlcohol abuseHIVUpper arm
2006
Patient treatment preferences for osteoporosis
Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arthritis & Rheumatism 2006, 55: 729-735. PMID: 17013870, PMCID: PMC1626097, DOI: 10.1002/art.22229.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overBone Density Conservation AgentsCross-Sectional StudiesDiphosphonatesDose-Response Relationship, DrugFemaleFractures, BoneHealth Care SurveysHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedOsteoporosisParathyroid HormonePatient CompliancePatient SatisfactionRecombinant ProteinsRisk AssessmentSurveys and QuestionnairesConceptsPreferred treatment optionRoute of administrationPatient's preferred treatment optionRecombinant human parathyroid hormoneOsteoporosis treatment optionsTreatment optionsAnnual infusionPatient preferencesTreatment preferencesIntravenous bisphosphonatesTreatment choiceRisk of vertebralTreatment-naive participantsPatients' treatment preferencesLong-term adherenceIndividual patient preferencesHuman parathyroid hormoneOral bisphosphonatesOsteoporosis medicationsWeekly bisphosphonatesWeekly pillConjoint analysis questionnaireOral medicationsHip fractureFuture fracturesPatient willingness to take teriparatide
Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Education And Counseling 2006, 65: 237-244. PMID: 16965888, PMCID: PMC1769517, DOI: 10.1016/j.pec.2006.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonAdministration, OralAgedAged, 80 and overBone Density Conservation AgentsChoice BehaviorConnecticutDrug Administration ScheduleFemaleFractures, BoneHealth Knowledge, Attitudes, PracticeHealth Services Needs and DemandHumansInjections, SubcutaneousMiddle AgedMultivariate AnalysisOsteoporosis, PostmenopausalPatient Acceptance of Health CarePostmenopauseRisk AssessmentSocioeconomic FactorsSurveys and QuestionnairesTeriparatideWomenConceptsDaily subcutaneous injectionsTreatment preferencesSubcutaneous injectionFuture fracturesMost womenAbsolute fracture riskTreatment of osteoporosisNovel treatment approachesConjoint analysis questionnairePostmenopausal womenAdaptive conjoint analysis questionnaireDaily injectionsPoor adherenceEfficacy advantageFracture riskPatients' willingnessClinical studiesAge 71Bone densitometryEffective treatmentNumber of subjectsTreatment approachesT-scoreOlder adultsWomen